Telix Pharmaceuticals Ltd ADR (TLX): Next-Year EPS Estimate 173.27%
As of 2026-05-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 173.27%. Featured in our EPS revision report on 2026-04-13.
On 2026-05-19, analyst consensus for TLX's next-year EPS growth shifted from 175.50% to 173.27% — a negative change of 2.23 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 306.33%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 173.27%
- EPS growth this year
- 306.33%
- EPS next quarter (est)
- N/A
- Last price
- $10.28
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-20 | 173.27% | 306.33% | N/A | $10.28 |
| 2026-05-19 | 173.27% | 306.33% | N/A | $10.17 |
| 2026-05-18 | 175.50% | 305.04% | N/A | $10.28 |
| 2026-05-17 | 175.50% | 305.04% | N/A | $10.56 |
| 2026-05-14 | 175.50% | 305.04% | N/A | $10.86 |
| 2026-05-13 | 175.50% | 305.04% | N/A | $10.52 |
| 2026-05-12 | 175.50% | 305.04% | N/A | $10.39 |
| 2026-05-11 | 175.50% | 305.04% | N/A | $10.83 |
| 2026-05-10 | 175.50% | 305.04% | N/A | $10.68 |
| 2026-05-07 | 175.50% | 305.04% | N/A | $10.66 |
| 2026-05-06 | 175.50% | 305.04% | N/A | $11.11 |
| 2026-05-05 | 175.50% | 305.04% | N/A | $11.04 |
| 2026-05-04 | 173.92% | 307.09% | N/A | $11.15 |
| 2026-05-03 | 171.73% | 308.37% | N/A | $11.26 |
| 2026-04-30 | 171.73% | 308.37% | N/A | $11.00 |
| 2026-04-29 | 173.27% | 306.33% | $0.02 | $10.43 |
| 2026-04-28 | 173.27% | 306.33% | $0.02 | $10.44 |
| 2026-04-27 | 173.27% | 306.33% | $0.02 | $10.40 |
| 2026-04-26 | 173.27% | 306.33% | $0.02 | $10.56 |
| 2026-04-24 | 173.27% | 306.33% | $0.02 | $10.56 |
| 2026-04-23 | 173.27% | 306.33% | $0.02 | $10.19 |
| 2026-04-22 | 173.27% | 306.33% | $0.02 | $10.33 |
| 2026-04-21 | 173.27% | 306.33% | $0.02 | $10.23 |
| 2026-04-20 | 173.27% | 306.33% | $0.02 | $10.73 |
| 2026-04-19 | 173.27% | 306.33% | $0.02 | $10.74 |
| 2026-04-16 | 180.16% | 297.87% | $0.02 | $10.74 |
| 2026-04-15 | 180.16% | 297.87% | $0.02 | $10.66 |
| 2026-04-14 | 184.64% | 290.39% | $0.02 | $10.70 |
| 2026-04-13 | 184.64% | 290.39% | $0.02 | $11.24 |
| 2026-04-12 | 181.44% | 292.09% | $0.02 | $10.54 |
Reports Featuring TLX
Recent News
- Telix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswire
- FDA Accepts NDA for TLX101-Px (Pixclara)GlobeNewswire
Screen Performance
Aggregate stats across all 1713 tickers our top-EPS-revision screen has flagged over the past 49 days.
- Median return since detection
- +2.8%
- % of tickers in the green
- 58%
- Median return on winners
- +15.1%
- Large revisions captured
- 630
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Telix Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-05-20, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 173.27%, based on analyst consensus.
When was the latest EPS estimate revision for TLX?▾
The most recent revision occurred on 2026-05-19, when analysts adjusted the next-year EPS growth estimate from 175.50% to 173.27%.
What sector and industry does Telix Pharmaceuticals Ltd ADR belong to?▾
Telix Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TLX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports